177 related articles for article (PubMed ID: 21098256)
1. Complementarity-determining region 3 size spectratypes of T cell receptor beta chains in CD8+ T cells following antiviral treatment of chronic hepatitis B.
Ma SW; Li YY; Zhang GW; Huang X; Sun J; Li C; Abbott WG; Hou JL
Antimicrob Agents Chemother; 2011 Feb; 55(2):888-94. PubMed ID: 21098256
[TBL] [Abstract][Full Text] [Related]
2. Telbivudine versus lamivudine in patients with chronic hepatitis B.
Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
[TBL] [Abstract][Full Text] [Related]
3. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
[TBL] [Abstract][Full Text] [Related]
4. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
[TBL] [Abstract][Full Text] [Related]
5. [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
Moon YM; Hwang SG; Kim BS; Rim KS; Cho M; Kim DJ; Han JY; Kim YS; Choi HS; Ahn SH
Korean J Hepatol; 2007 Dec; 13(4):503-12. PubMed ID: 18159148
[TBL] [Abstract][Full Text] [Related]
6. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
[TBL] [Abstract][Full Text] [Related]
7. [The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].
Jia JD; Hou JL; Yin YK; Xu DZ; Tan DM; Niu JQ; Zhou XQ; Wang YM; Zhu LM; He YW; Ren H; Wan MB; Chen CW; Wu SM; Chen YG; Xu JZ; Wang QH; Wei L; Ma H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):342-5. PubMed ID: 17524265
[TBL] [Abstract][Full Text] [Related]
8. [Telbivudine treatment on cirrhosis resulting from chronic hepatitis B].
Liang J; Han T; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2009 Jan; 17(1):24-7. PubMed ID: 19203447
[TBL] [Abstract][Full Text] [Related]
9. [Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B].
Xie DY; Lin BL; Chen FJ; Deng H; Chong YT; Zhang XH; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2010 Sep; 18(9):646-50. PubMed ID: 20943073
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Chan HL; Heathcote EJ; Marcellin P; Lai CL; Cho M; Moon YM; Chao YC; Myers RP; Minuk GY; Jeffers L; Sievert W; Bzowej N; Harb G; Kaiser R; Qiao XJ; Brown NA;
Ann Intern Med; 2007 Dec; 147(11):745-54. PubMed ID: 17909201
[TBL] [Abstract][Full Text] [Related]
11. Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment.
Lv G; Ying L; Ma WJ; Jin X; Zheng L; Li L; Yang Y
Virol J; 2010 Aug; 7():207. PubMed ID: 20807412
[TBL] [Abstract][Full Text] [Related]
12. Rapid downregulation of programmed death-1 and interferon-γ-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B.
Hou FQ; Wu XJ; Wang Y; Chen J; Liu YZ; Ren YY; Song G; Ding YP; Yu M; Wang GQ
J Viral Hepat; 2013 Apr; 20 Suppl 1():18-26. PubMed ID: 23458521
[TBL] [Abstract][Full Text] [Related]
13. Telbivudine versus lamivudine in patients with chronic hepatitis B.
Tillmann HL; McHutchison JG
N Engl J Med; 2008 Apr; 358(14):1517; author reply 1517-8. PubMed ID: 18385505
[No Abstract] [Full Text] [Related]
14. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
Ma SW; Huang X; Li YY; Tang LB; Sun XF; Jiang XT; Zhang YX; Sun J; Liu ZH; Abbott WG; Dong YH; Naoumov NV; Hou JL
J Hepatol; 2012 Apr; 56(4):775-81. PubMed ID: 22173154
[TBL] [Abstract][Full Text] [Related]
15. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
Safadi R; Xie Q; Chen Y; Yin YK; Wei L; Hwang SG; Zuckerman E; Jia JD; Lopez P
Liver Int; 2011 May; 31(5):667-75. PubMed ID: 21040410
[TBL] [Abstract][Full Text] [Related]
17. Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients.
Tang TJ; de Man RA; Kusters JG; Kwekkeboom J; Hop WC; van der Molen RG; Schalm SW; Janssen HL
J Med Virol; 2004 Feb; 72(2):215-22. PubMed ID: 14695662
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B.
Nan XP; Zhang Y; Yu HT; Sun RL; Peng MJ; Li Y; Su WJ; Lian JQ; Wang JP; Bai XF
Viral Immunol; 2012 Feb; 25(1):21-8. PubMed ID: 22233255
[TBL] [Abstract][Full Text] [Related]
19. TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B.
Lai Q; Ma S; Ge J; Huang Z; Huang X; Jiang X; Li Y; Zhang M; Zhang X; Sun J; Abbott WG; Hou J
PLoS One; 2014; 9(2):e88475. PubMed ID: 24551107
[TBL] [Abstract][Full Text] [Related]
20. Telbivudine in the treatment of chronic hepatitis B.
Nash K
Adv Ther; 2009 Feb; 26(2):155-69. PubMed ID: 19225726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
